Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.

Clinical pharmacology and therapeutics - 1 May 2017

Arwood M J, Deng J, Drozda K, Pugach O, Nutescu E A, Schmidt S, Duarte J D, Cavallari L H

Abstract excerpt

Achieving therapeutic anticoagulation efficiently with warfarin is important to reduce thrombotic and bleeding risks and is influenced by genotype. Utilizing data from a diverse population of 257 patients who received VKORC1 and CYP2C9 genotype-guided warfarin dosing, we aimed to examine genotype-associated differences in anticoagulation endpoints and derive a novel pharmacogenetic nomogram to more optimally dose...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Dose-Response Relationship, Drug

Share to Endpoint Determination

Share to Pharmacogenetics

Share to Vitamin K Epoxide Reductases

Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 28032893
DOI: 10.1002/cpt.558
PMCID: PMC5395307

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anticoagulation endpoints with clinical implementation of warfarin pharmacogenetic dosing in a real-world setting: A proposal for a new pharmacogenetic dosing approach.PMID 28032893Read ↗

Genotype-guided dosing of warfarin through modeling and simulation.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing.Semantic proximity Read ↗

A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation.Semantic proximity Read ↗

A randomized trial of genotype-guided dosing of warfarin.Semantic proximity Read ↗

Role of Warfarin Pharmacogenetic Testing in Clinical PracticeSemantic proximity Read ↗

Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinSemantic proximity Read ↗

A pharmacogenetic versus a clinical algorithm for warfarin dosing.Semantic proximity Read ↗

A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity.Semantic proximity Read ↗

Warfarin pharmacogenomics: recommendations with available patented clinical technologies.Semantic proximity Read ↗

Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study.Semantic proximity Read ↗

A retrospective cohort study of pharmacogenetics of warfarin dosing in Chinese Adults with nonvalvular atrial fibrillationSemantic proximity Read ↗

Warfarin Pharmacogenetic Trials: Is there a Future for Pharmacogenetic-Guided Dosing?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.